Navigation Links
EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435

DURHAM, N.C., May 30 /PRNewswire/ -- Dr. George C. Clark of Xenobiotic Detection Systems (XDS) and Dr. Michael Denison at the University of California Davis, with support from the Superfund Basic Research Program, have developed a rapid and inexpensive recombinant cell bioassay system for the detection and relative quantification of dioxin-like chemicals. Dioxin-like chemicals are some of the most toxic chemicals known.

The CALUX(R) by XDS (Chemical Activated LUciferase Gene Expression) system has recently been published and is posted under "New Methods" on the SW-846 website. In March 2008, the EPA's Office of Solid Waste (OSW) Organic Methods Workgroup formally reviewed and approved Method 4435 for inclusion into Test Methods for Evaluating Solid Waste, Physical/Chemical Methods, also known as SW-846. The XDS-CALUX system consists of a unique sample processing method linked with a sensitive gene expression cell bioassay detection system providing unique sensitivity and selectivity for quantifying dioxin-like chemicals.

The XDS-CALUX(R) bioassay costs are 40%-70% lower than the traditional High Resolution Gas Chromatography/Mass Spectrometry (HR GC/MS) that was the old singular analysis standard. Xenobiotic Detection Systems Method 4435 provides an excellent screening tool to rapidly detect and quantify these ubiquitous and toxic environmental contaminants.

"This approval exemplifies the assay's versatility and is another major step for XDS," says President of XDS, Dr. George Clark. "Having been certified in the European Union since 2002 to primarily monitor feed and food it is wonderful to receive accreditation here in the U.S. Our screening analysis method is faster, far more affordable, and in many cases even more sensitive than the traditional HR GC/MS. The EPA's approval will allow us to better serve our clients and safeguard the environment from these toxic contaminants."

Research Institutes Worldwide using XDS-CALUX(R) Technology includes the United States: US FDA and University of California Davis. Asia: Hiyoshi Corporation of Japan, Cheng-Shiu University, Taiwan. Europe: Scientific Institute of Public Health, Brussels, Belgium, Federal Feed Laboratory, Tervuren, Belgium, and the National Veterinary Research Institute, Pulawy, Poland.

Development of the XDS-CALUX(R) technology was funded in part by Superfund Basic Research Program Grant (ES04699), and by Small Business Innovation Research Grants from the National Institute of Environmental Health Sciences (ES 08372-01 and ES 08372-02).

Additional information: XDS ( or call 1-888-D-I-O-X-I-N-S

(R) "Registered US Trademark and Patent Office"

SOURCE Xenobiotic Detection Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
Post Your Comments:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):